Re-examining osteoarthritis therapy from a developmental biologist's perspective

Biochem Pharmacol. 2019 Jul:165:17-23. doi: 10.1016/j.bcp.2019.03.020. Epub 2019 Mar 26.

Abstract

Osteoarthritis is the most prevalent musculoskeletal disorder and one for which there is no disease modifying therapy available at present. Our current understanding of the disease mechanism of osteoarthritis is limited owing to a lacuna of knowledge about the development and maintenance of articular cartilage that is affected during osteoarthritis. All current therapeutic strategies aim at countering inflammation which though mitigates pain but does not arrest the progressive degeneration of articular cartilage. During osteoarthritis, articular cartilage expresses markers for transient cartilage differentiation. Moreover, blocking transient cartilage differentiation is sufficient for halting the progression of experimental osteoarthritis. A developmental biology inspired approach that combines restoration of tissue microenvironment, supplementation with engineered cartilage and built in mechanism to prevent transient cartilage differentiation could be an avenue for developing a disease modifying therapy for osteoarthritis.

Keywords: Articular cartilage; Differentiation; Osteoarthritis developmental biology; Transient cartilage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cartilage, Articular / cytology
  • Cell Differentiation
  • Humans
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / pathology
  • Signal Transduction / physiology
  • Tissue Engineering